Circadian rhythm defects in Prader-Willi syndrome neurons

A Kaitlyn Victor1, Tayler Hedgecock2, Chidambaram Ramanathan3

  • 1Department of Neurology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

HGG Advances
|March 2, 2025
PubMed

Insights

Prader-Willi syndrome (PWS) neurons show disrupted circadian rhythms. The drug longdaysin normalized the shorter circadian period in PWS neurons, offering a potential therapeutic avenue for sleep dysfunction.

Area of Science:

  • Neuroscience
  • Genetics
  • Chronobiology

Background:

  • Prader-Willi syndrome (PWS) is a genetic imprinting disorder affecting neurodevelopment and causing intellectual disability and autism risk.
  • PWS is linked to the loss of paternal gene expression in the 15q11.2-q13 region, impacting genes like MAGEL2.
  • Patients with PWS frequently experience sleep disorders, and animal models show disrupted circadian rhythms.

Purpose of the Study:

  • To investigate circadian clock function in neurons derived from Prader-Willi syndrome patients.
  • To establish an in vitro model for studying PWS-related circadian rhythm disruptions.
  • To explore potential therapeutic interventions for PWS circadian dysfunction.

Main Methods:

  • Dental pulp stem cells (DPSCs) from PWS patients and controls were differentiated into neurons.
  • A Per2 promoter-driven luciferase reporter (Per2:luc) was introduced to assess circadian rhythms via bioluminescence.
  • Kinetic measurements of luciferase activity were performed over several days to analyze circadian period length.

Main Results:

  • Significant differences in circadian period length were observed between PWS neurons and control neurons.
  • Treatment with the small molecule longdaysin effectively lengthened the shorter circadian period in PWS neurons.
  • The study successfully modeled PWS circadian dysfunction in vitro.

Conclusions:

  • Neurons derived from PWS patients exhibit altered circadian clock function.
  • Longdaysin demonstrates potential as a therapeutic agent for correcting circadian rhythm abnormalities in PWS.
  • This research provides a foundation for developing drug discovery assays for PWS-related sleep and circadian disorders.